STOCK TITAN

IDEAYA Biosciences to Participate in Investor Conferences in December 2021

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

IDEAYA Biosciences (NASDAQ: IDYA), a precision medicine oncology company, announced its participation in investor conferences in December 2021. Notably, they will host a fireside chat at the Evercore ISI HealthConX Conference on December 2, 2021, at 10:30 am ET, featuring CEO Yujiro Hata. A live audio webcast will be available on their website, with replays accessible for 30 days. IDEAYA focuses on discovering targeted therapeutics using synthetic lethality, enhancing treatment for specific patient populations through molecular diagnostics.

Positive
  • None.
Negative
  • None.

SOUTH SAN FRANCISCO, Calif., Nov. 30, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in investor conferences in December 2021.

Evercore ISI HealthConX Conference
Thursday, December 2, 2021 at 10:30 am ET

  • Fireside Chat with Yujiro Hata, Chief Executive Officer, hosted by Josh Schimmer, M.D., M.B.A, Fundamental Research Analyst

A live audio webcast of the event will be available, as permitted by conference host, at the "Investors/News and Events/Investor Calendar" section of the IDEAYA website at https://ir.ideayabio.com/events.  A replay of available webcasts will be accessible for 30 days following the live event.

About IDEAYA Biosciences

IDEAYA is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.  IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies.  IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets. 

Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's Quarterly Report on Form 10-Q filed on November 15, 2021 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-to-participate-in-investor-conferences-in-december-2021-301433559.html

SOURCE IDEAYA Biosciences, Inc.

FAQ

When is IDEAYA's participation in the Evercore ISI HealthConX Conference?

IDEAYA Biosciences will participate in the Evercore ISI HealthConX Conference on December 2, 2021, at 10:30 am ET.

Who will be speaking at the IDEAYA investor conference?

CEO Yujiro Hata will speak at the conference, hosted by Josh Schimmer, M.D.

Where can I find the webcast of IDEAYA's conference participation?

The live audio webcast will be available on IDEAYA's website under the 'Investors/News and Events/Investor Calendar' section.

What is the focus of IDEAYA Biosciences?

IDEAYA Biosciences focuses on precision medicine, specifically developing targeted therapeutics through synthetic lethality.

How long will the conference replay be available?

Replays of the conference webcasts will be accessible for 30 days following the live event.

IDEAYA Biosciences, Inc.

NASDAQ:IDYA

IDYA Rankings

IDYA Latest News

IDYA Stock Data

2.37B
86.43M
1.04%
100.26%
11.13%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SOUTH SAN FRANCISCO